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Abstract Compliance to oral bisphosphonates is subopti-
mal, with negative consequences of increased healthcare
utilization and less effective fracture risk reduction.
Extending dose interval increased adherence only moder-
ately. We used literature derived from multiple chronic
conditions to examine the problem of noncompliance with
osteoporosis medication. We reviewed the literature on
adherence to osteoporosis medication as well as that across
multiple chronic conditions to understand what is known
about the cause of the poor adherence. Poor compliance to
oral medications is due mostly, not to forgetfulness, but to
deliberate choice. Gender differences and style of health-
care management also play a role. Preliminary data suggest
psychobehavioral interventions may help to improve
motivation. We need to understand better reasons for poor
compliance before effective interventions can be developed.
Forgetfulness is only a small part of poor compliance.





The primary challenge in treating chronic illness today is
that many chronically ill patients do not take their
prescription medications correctly. As the US Surgeon
General C. Everett Koop has said, “Drugs don’t work in
patients who don’t take them....” There has been much
concern about the negative consequences of poor compli-
ance and persistence with oral osteoporosis medications.
This article will briefly review these issues and, more
specifically, will address possible reasons why patients may
not take their oral osteoporosis therapies as directed, and
suggest some potential solutions and future research. We
will focus on oral bisphosphonates since the majority of the
prescriptions for a medication for fracture prevention are
for an oral bisphosphonate.
Compliance and persistence with therapy
What has become apparent in research done during the last
few years is that many patients discontinue oral medications
for osteoporosis soon after treatment initiation, with a rapid
drop in persistence in the first 3 months, followed by a slower
decline over ensuing months. For example, persistence on
daily bisphosphonate therapy has varied between 25% and
35% persistence at 1 year [1]. Persistence with weekly
bisphosphonate therapy at 1 year is between 35% and 45%, a
rate not substantially better [1]. Some improvement in
persistence was seen in one study with monthly bisphosph-
onate therapy using administrative claims data, but this
improvement has not been confirmed in other studies [2–4].
Adherence to estrogen agonists/antagonists such as ralox-
ifene may be somewhat higher [5], as well as anabolic
agents such as teriparitide which require daily subcutane-
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onate medications depends on the methodology used,
whether medication possession ratio or persistence over a
specific time period is used as well as the definition of
the refill gap. This poor persistence seen with oral
bisphosphonates does not differ substantially from the
persistence to oral medications prescribed for other
largely asymptomatic chronic conditions such as hyper-
tension [7] and hypercholesterolemia [8]. Osteoporosis
itself is asymptomatic until a fracture occurs, and some
patients can have multiple vertebral fractures before
symptoms appear.
Evidence suggests across multiple therapeutic areas that
many patients take drugs incorrectly, infrequently, or not at
all. A 2002 Harris Interactive Study [9] showed that
approximately 18% of patients taking medications for one
or more chronic illnesses had not filled their prescriptions at
all, 26% had delayed filling their prescriptions, 14% took a
prescription medication in a smaller dose than prescribed,
approximately 30% had taken a prescription medication
less often than prescribed, and approximately 21% had
stopped taking medication sooner than prescribed. While
such a study has not yet been done in patients with
osteoporosis, we anticipate that the results of one would be
similar to those reported here.
Noncompliance and nonpersistence can occur at three
discrete points. Patients can be noncompliant by not
filling their prescription; they can be noncompliant by not
initially taking their medicine as directed by their
physician (correct dosing and time and manner of
administration), or they can be noncompliant by missing
doses. They can also stop their medication without telling
their healthcare providers (nonpersistence).
Consequences of poor compliance and persistence
Poor compliance and persistence with osteoporosis medica-
tions lead to diminished medication efficacy and, therefore, to
less suppression of bone turnover [10] and lower gains in
bone mineral density [11]. These in turn lead to higher
fracture rates, [12–15], medical costs, and greater healthcare
utilization including higher hospitalization rates [16].
Some refill compliance studies in patients with osteopo-
rosis have examined the relationship between such compli-
ance and fracture. Siris et al. [17] found that minimal and/or
no effect on fracture risk is with refill compliance below
50%, and a curvilinear decrease in probability of fracture
is with refill compliance over 50%. In contrast, Curtis et
al. did not find a threshold level of compliance below
which there was no fracture reduction benefit, but rather
a curvilinear effect throughout all ranges of refill
compliance [18]. Similarly, among patients with osteopo-
rosis by bone mineral density criteria, Rabenda et al. [14]
found a linear relationship between hip fracture reduction
benefit and medication possession ratio throughout the
entire range of refill compliance.
Perhaps the most striking point was made by Feldstein
[19] who found similar time to first fracture over an 8-year
period of patients with osteoporosis as defined by bone
density or fracture in patients who were treated with oral
bisphosphonates versus those who were not treated with
an osteoporosis medication. Her study suggests that
although oral bisphosphonates are efficacious in randomized
clinical trials (within which persistence and compliance
are typically high), their efficacy does not translate to the
community setting when patients do not fill their
prescriptions, do not take their medications as prescribed,
and are not persistent.
Reasons for noncompliance
Direct experience of adverse effects (such as stomach
upset from an oral bisphosphonate) accounts for a
significant proportion of nonpersistence and noncompli-
ance. Even without directly experienced side effects,
however, patients may stop their medication for a
number of reasons [20]. They may not believe that they
have osteoporosis or that they are not at much risk of
fracture (e.g., they do not have a problem that requires a
solution). For some individuals, future potential health
issues are not a salient issue for them in their lives, such
that even if they acknowledge a high risk of future
fractures, they place a lower value on interventions to
reduce that risk [21, 22]. Patients may be skeptical of the
effectiveness of the medication or worried about long-
term harm from or feeling dependent upon medication.
Even if they do acknowledge that the medication does
effectively reduce fractures, they may believe they can
address the problem adequately through non-medicinal
interventions (e.g., nutritional interventions such as
calcium and vitamin D and exercise). The cost of the
medication may be a barrier for them [23]. Any
combination of these reasons may lead a person to choose
nonpersistence with fracture prevention medication. Dis-
crete choice experiments suggest that patients weigh
perceived risks and benefits when they form their
intention as to whether they take a medication or not.
They consider the perceived benefit of the medication, its
cost (i.e., cost and time), and perceived risks of side
effects [24, 25]. As many as one fifth or more of patients
do not fill their prescriptions [26].
Even if patients form an intention to take medication
for osteoporosis, they may have difficulty executing
medication use behavior in the context of their daily
22 Osteoporos Int (2011) 22:21–26lives. Lack of perceived ability to take the medication as
prescribed (poor self-efficacy) [27], complex dosing
schedules that interfere with daily activities, lack of social
support to aid their medication use activities, and simply
forgetting to take the medication may result in non-
persistence or noncompliance [20] In these instances, poor
compliance may be unintentional.
As noted previously, in the 2002 Harris Interactive
Study of Persistence and Compliance [9], patients were
asked why they did not fill prescriptions or comply with
drug regimens. Twenty-four percent of the patients
suggested that they occasionally forget to refill a prescrip-
tion, while another 20% did not want to experience real or
perceived side effects. Cost was a barrier for 17% of these
patients, and another 14% felt they did not really need the
drug. Interestingly, this study revealed that another
important factor in compliance and persistence may be
the patient’s own management style. The researchers
found that, in chronic diseases, patients for whom
maintaining a sense of control is important are most likely
not to fill a prescription, fill a prescription on time,
continue taking a prescription, and take it as frequently
as prescribed or in sufficient doses than patients who are
less concerned about maintaining a sense of control.
Future research is needed to ascertain whether or not
these individuals are more likely to feel dependent on
medication when using it, and if that is the source of
their sense of lack of control associated with its use. The
Harris study also found that there were gender differ-
ences in medication behaviors, with women less likely
than men to report compliance with prescribed drug
regimens; however, other studies have reported lower
compliance among men [28].
The perspectives of physician and patient often differ
substantially [20, 29]. Although both physicians and
patients consider efficacy, safety, and cost, they are likely
to differ in their estimates or beliefs about these in part
because they have different belief systems and use
different sources of information. Patients increasingly
gather information from the Internet, while also depending
on peers, friends, and family. Physicians, on the other
hand, rely on published data from randomized clinical
trials, professional guidelines, and opinions of key thought
leaders. Patients often base their safety concerns on both
real and perceived side effects. Physicians think about
costs to the healthcare system as well as to the patient
while patients focus on their own out of pocket costs.
Physicians may concentrate on negative messaging (e.g.,
if you do not take your medication you will fracture and
you will be in a wheelchair) while patients respond to
positive messaging (if you take your medicine you will
h a v eab e t t e rq u a l i t yo fl i f ea n db ea b l et op l a yw i t hy o u r
grandchildren) [30].
Generalizability
In this review, we have focused on oral bisphosphonates
since the majority of scripts are for oral bisphospho-
nates. Most studies have focused on oral bisphospho-
nates. There is some modest data on raloxifene (ref)
which shows similarly poor compliance on therapy and
data on rhPTH(1–34) which also shows poor compliance
to this daily injectable therapy. We do not know
compliance on parenteral bisphosphonates but if we are
correct that a substantial proportion of poor persistence
is intentional, then the use of IV drugs is not likely to
fully address the problem of poor persistence. An
individual needs to go to a healthcare provider to get
the IV therapy. There has been no extensive study of
compliance to vitamin D, but studies of compliance to
vitamin D would be worthwhile.
How we can improve compliance and persistence
The research literature suggests that the most effective
compliance and persistence intervention may simply be to
increase interaction with healthcare providers. Clowes et al.
[31] did a randomized clinical trial to study compliance and
persistence in osteoporosis with patients randomized to one
of three groups: no monitoring, nurse monitoring, and nurse
plus bone marker monitoring. Both of the monitored groups
showed better persistence than did the no-monitoring
group, but there was no significant difference between
nurses monitoring alone compared to nurse plus marker
monitoring. In the Delmas [32] IMPACT trial, patients who
had a positive response to therapy as judged by urine
biomarkers and were given positive feedback had better
adherence (i.e., compliance) than patients who received
negative feedback from biomarkers.
Therapeutic interventions to improve medication-related
behaviors across multiple chronic conditions have often
failed. In a review by Haynes [33], only 36 out of 81
adherence interventions led to improved outcomes with
modest improvements in persistence and clinical outcomes.
Most of the interventions have emphasized use of pill
reminders, pill organizers, increasing convenience which do
not address intentional poor compliance. The majority of
the successful interventions involved more than one type of
intervention (e.g., education combined with self-
management) [33, 34] and involved some level of engaging
the patient to influences, health beliefs, and attitudes they
have regarding their underlying disease and the recommen-
ded medication.
Compliance and persistence are extremely important for
a variety of people with interest and investment in
osteoporosis. Stakeholders for compliance and persistence
Osteoporos Int (2011) 22:21–26 23include healthcare providers, pharmaceutical companies,
family, friends, and pharmacists; however, the major
stakeholder—the one in the middle of this circle—is the
patient. All of these stakeholders could play a potential role
in improving compliance and persistence.
Opportunities to improve compliance and persistence
occur at several points after a patient receives the diagnosis
of osteoporosis. While writing the prescription, healthcare
providers could attempt to identify high-risk patients who
initially may not even fill the prescription. High-risk
patients could be identified [35] by using a questionnaire
or by review of compliance with other medications [36].
After a patient fills a prescription, more traditional patient-
and physician-centered strategies might enhance patient
behaviors. Patient-centered solutions include use of alter-
native packaging [37], loyalty incentive programs, letter,
texting or e-mail reminder programs [38, 39], and patient
educational tools including use of call centers [40].
Lowering cost may have a significant positive effect, but
other factors are even more important [23]. Strategies for
physicians have included electronic reminders, education of
the importance of compliance and persistence, and pay for
performance.
However, both traditional patient- and physician-
centered strategies have not been successful in improving
compliance and persistence [41] in part due to participant
bias in these interventions. Patients who participate in these
programs are often the patients most interested and invested
in their care (e.g., for whom the health value of the
medication is high and understand the connection between
their health behaviors and health outcomes). Patients for
whom the health value of the medication is lower are more
likely to be noncompliant and are unlikely to participate in
these programs. These individuals may tend to be more
passive in managing their health and may not see the
connection between their own health behaviors and the
resulting health outcomes.
Recently, commercial programs have attempted to
improve compliance and persistence [42] by adding patient
support through motivational interviewing techniques [43,
44], which attempt to modify patient behaviors and
“activate” patients to improve their health behaviors. These
behavioral techniques help patients by identifying personal
goals, by helping them understand how fractures would
impede their ability to realize those goals, and by using
interviewing techniques done by behavioral coaches to help
motivate patients to be able to make a more realistic
appraisal of the risks and benefits of medication use.
These techniques may help improve patients’ self-efficacy
[27] or confidence that they can take their medication in the
context of their daily lives and become better self-
managers. Unfortunately, such behavioral interventions
are time intensive and costly. However, such interven-
tions could be cost-effective if they result in significant
healthcare savings from preventing fractures. What we
need is to be able to deliver a behavioral intervention
with cost-effective technology. One such possibility is to
use the Internet or DVDs to disseminate educational
material to activate patients based on elicited patient
preferences and health beliefs.
Poor persistence and compliance is a significant
problem in the management of osteoporosis. The primary
reason patients with osteoporosis do not take their
medicines is most likely not simply forgetting to do so.
The majority of patients are actively choosing not to take
their medications. Why they make these choices varies.
The effect of improving patients taking their medications
by 20% is equivalent to a roughly 20% improvement in
efficacy [45]. We need to be thinking about interventions
which not only extend dosing intervals but also utilize
multifaceted strategies to improve compliance and persis-
tence. These must start when the prescription is written
and continue throughout the entire medication-taking
interval.
Further research
Future research on compliance and persistence should
be concentrated in three main areas. First, we need to
better understand the process by which patients form
intentions to take or not take recommended medication.
Secondly, we need to understand the roles of patient
time preference in patient decision-making, which refers
to the degree that patients are willing to expend
resources such as time, money, or bother now to
prevent adverse events such as fracture which may or
may not happen in the future. We also need to
understand patient risk preferences in terms of fracture
risk and side effects. What level of fracture risk
motivates a patient to take a medication and, similarly,
what level of perceived side effects will motivate a
patient to discontinue a medication or not fill the
prescription? Finally, using this information, we need
to develop means to help healthcare providers identify
patients who are at high risk of poor compliance and/or
persistence. This may include questionnaires [35]o rb y
reviewing persistence to other chronic medications [36].
We then need to develop interventions solidly based on
educational theory which will activate those patients at
high risk of osteoporosis to be more involved in their
care and become more compliant and persistent with
medication regimens. These interventions may require
the services of allied health professionals skilled in
behavioral coaching and motivational interviewing tech-
niques. Such programs will of course carry a direct
24 Osteoporos Int (2011) 22:21–26medical cost. Research in the future will be required to
estimate how effective such programs are in improving
compliance with osteoporosis medications, and how
cost-effective are these interventions.
Conclusions
Compliance and persistence with osteoporosis therapy is
less than optimal. However, compliance and persistence in
osteoporosis is not significantly different from other
asymptomatic chronic conditions. Most of the poor medi-
cation behavior with osteoporosis medication is probably
intentional rather than unintentional. There is a need to
develop multifaceted interventions to improve compliance
and persistence with osteoporosis medications.
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